Skip to main content

News Room

Smiling woman patient with healthcare worker

QUALIGEN DIAGNOSTICS ANNOUNCE AGREEMENT WITH AFAXYS GPO TO EXPAND ACCESS TO FASTPACK® IP QUANTITATIVE hCG TESTING IN WOMEN’S HEALTH

| Chembio | No Comments
QUALIGEN DIAGNOSTICS ANNOUNCE AGREEMENT WITH AFAXYS GPO TO EXPAND ACCESS TO FASTPACK® IP QUANTITATIVE hCG TESTING IN WOMEN'S HEALTH Carlsbad, C.A., USA / Strasbourg, France – March 20, 2026 –…
Typhoid bacteria background

CHEMBIO RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER

| Chembio | No Comments
CHEMBIO DIAGNOSTIC SYSTEMS, INC., A BIOSYNEX SUBSIDIARY, RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER Medford, N.Y., USA / Strasbourg, France – February 6,…

CHEMBIO ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION

| Chembio | No Comments
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION Medford, N.Y., USA / Strasbourg, France – January 22,…

CHEMBIO RECEIVES A GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA

| Chembio | No Comments
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA Chembio Diagnostic System, Inc. (Chembio), a wholly owned…

Subscribe to the Chembio Mailing List